These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 6724353)

  • 1. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
    Pippard MJ; Weatherall DJ
    Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in mild sideroblastic anaemias.
    Peto TE; Pippard MJ; Weatherall DJ
    Lancet; 1983 Feb; 1(8321):375-8. PubMed ID: 6130377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
    Taher A; Hershko C; Cappellini MD
    Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron chelate treatment of hereditary sideroblastic anemia complicated by hemochromatosis].
    Kremp L; Girot R; Alliot S; Najean Y; Douchain F; Hongre JF
    Arch Fr Pediatr; 1983; 40(6):475-7. PubMed ID: 6625846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron loading anaemias.
    Mehta BC; Pandya BG; Mehta JB; Bisariya BN
    J Assoc Physicians India; 1989 Dec; 37(12):754-6. PubMed ID: 2636578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.
    Cazzola M; Barosi G; Bergamaschi G; Dezza L; Palestra P; Polino G; Ramella S; Spriano P; Ascari E
    Br J Haematol; 1983 Aug; 54(4):649-54. PubMed ID: 6871111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma iron and erythrocytic glutathione peroxidase activity. A possible mechanism for oxidative haemolysis in iron deficiency anemia.
    Cellerino R; Guidi G; Perona G
    Scand J Haematol; 1976 Aug; 17(2):111-6. PubMed ID: 968443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA; Flynn DM; Barry M
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract]   [Full Text] [Related]  

  • 12. Chelation therapy in beta-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid.
    Peterson CM; Graziano JH; Grady RW; Jones RL; Markenson A; Lavi U; Canale V; Gray GF; Cerami A; Miller DR
    Exp Hematol; 1979 Feb; 7(2):74-80. PubMed ID: 371974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vitamin B6-sensitive hereditary sideroblastic anemia].
    Heller T; Höchstetter V; Basler M; Borck V
    Dtsch Med Wochenschr; 2004 Jan; 129(4):141-4. PubMed ID: 14724775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of iron overload in thalassemia].
    Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 17. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary iron overload].
    Galacteros F
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():44-8. PubMed ID: 9827215
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
    Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.